Research advances in the effects of orexin and its receptor-related drugs on depression
- VernacularTitle:食欲素及其受体相关药物对抑郁症影响的研究进展
- Author:
Zhaoshu JIANG
1
;
Ming CHENG
1
;
Jie YANG
1
;
Feng CAO
1
;
Zhen ZHANG
1
Author Information
1. College of Traditional Chinese Medicine Health Preservation，Guizhou University of Traditional Chinese Medicine，Guiyang 550025，China
- Publication Type:Journal Article
- Keywords:
orexin;
depression;
receptor antagonists;
clinical study
- From:
China Pharmacy
2025;36(4):496-500
- CountryChina
- Language:Chinese
-
Abstract:
Depression is a psychiatric disorder whose main symptoms include low mood， loss of interest， anxiety， sleep disturbances， and changes in appetite. Orexin， a neuropeptide located in hypothalamic neurons， has a wide range of projections throughout the central nervous system and is involved in various behavioral modulations related to depression. This study systematically reviewed the effects of orexin and its receptor-related drugs on depression and found that orexin could exert complex regulatory effects on multiple brain regions by binding to related receptors， affecting emotions， sleep， anxiety， etc. The abnormal state of expression of plasma orexin in patients with depression was found. Exogenous orexin-A， selective orexin receptor 1 antagonists （SORA1s）， selective orexin receptor 2 antagonists （SORA2s）， and dual orexin receptor antagonists （DORAs） have demonstrated antidepressant-like effects in various animal models of depression. Among them， clinical trials involving exogenous orexin-A are relatively scarce. Drugs related to SORA1s and SORA2s， such as JNJ-61393215 and Setorexant， have made significant progress in the treatment of depression. DORAs， such as Suvorexant， Lemborexant， and Daridorexant， are primarily used to treat insomnia. Notably， Suvorexant has also shown potential in alleviating symptoms of anxiety and depression.
